Penn Comprehensive Hemophilia Program, University of Pennsylvania School of Medicine, Philadelphia, PA, USA.
Haemophilia. 2009 Nov;15(6):1197-209. doi: 10.1111/j.1365-2516.2009.02066.x. Epub 2009 Jul 21.
The availability of safe replacement clotting factor concentrates together with effective antiviral drugs to treat human immunodeficiency and hepatitis C viruses and the provision of care at designated haemophilia treatment centres have resulted in a new phenomenon in haemophilia management - the ageing patient. Today, increasing numbers of persons with haemophilia (PWH) are middle-aged and older, and they face the same age-related health issues as the general population. The impact of these risks on PWH is unclear, however, and there is a paucity of information about how to manage comorbidities in this patient population. This review focuses on five comorbidities that uniquely affect older PWH: cardiovascular disease, liver disease, cancer, renal disease and joint disease. Available research is summarized and potential management approaches are suggested.
安全的替代凝血因子浓缩物的供应以及有效的抗病毒药物来治疗人类免疫缺陷和丙型肝炎病毒，加上在指定的血友病治疗中心提供护理，导致血友病管理出现了一个新现象——老年患者。如今，越来越多的血友病患者（PWH）已经进入中年和老年，他们面临着与普通人群相同的与年龄相关的健康问题。然而，这些风险对 PWH 的影响尚不清楚，并且关于如何管理这一患者群体的合并症的信息也很匮乏。这篇综述重点介绍了五种独特影响老年 PWH 的合并症：心血管疾病、肝病、癌症、肾病和关节疾病。总结了现有研究并提出了潜在的管理方法。
